Tracers / [225Ac]Ac-Macropa-PEG4-YS5

[225Ac]Ac-Macropa-PEG4-YS5

Also written as [Ac-225]Macropa-PEG4-YS5; Ac-225-Macropa-PEG4-YS5
Radionuclide
Ac-225 t½ 14284.8 min
Modality
Therapy
Production route
Stage
Syntheses indexed
4

What it is

Compound class
Macropa-conjugated anti-CD46 monoclonal antibody (radioimmunoconjugate) with PEG4 linker
Target / mechanism
CD46-targeted alpha therapy using antibody YS5 PMID 38389832
Clinical application
Targeted alpha particle radioimmunotherapy for metastatic castration-resistant prostate cancer, including PSMA-negative disease, via CD46 targeting PMID 39945595
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
40909732
2025 bioRxiv
Manual synthesisSPE99.5%Macropa-PEG4-YS539945595
2025 Clin Cancer Res
The alpha-particle therapy agent [225Ac]Macropa-PEG4-YS5 was prepared according to the previously reported protocol (28). — with an isolated yield of 0.85 MBq
Manual synthesisSPE>95%>95%Macropa-PEG4-YS538389832
2024 Theranostics
A standard one-step process was used for radiolabeling. — we achieved a >95% radiochemical yield when labeling Macropa-PEG0/4/8-YS5 with 225Ac
Manual synthesisSPE96.97%~100%Macropa-PEG4-YS538389832
2024 Theranostics
The mixture was incubated at 25 oC for 1 h. — 96.97% for PEG4

Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-PEG4-YS5, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39945595: 'Macropa-PEG4-YS5'.